{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:50:12Z","timestamp":1794433812696,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vaillantfonds"},{"name":"Dutch Cardiovascular Alliance Consortium IMPRESS","award":["2020B004"],"award-info":[{"award-number":["2020B004"]}]},{"name":"Dutch Cardiovascular Alliance Consortium IMPRESS","award":["2020B004"],"award-info":[{"award-number":["2020B004"]}]},{"name":"Dutch Heart Foundation CVON RECONNEXT consortium","award":["2020B008"],"award-info":[{"award-number":["2020B008"]}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09120232310119"],"award-info":[{"award-number":["09120232310119"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardiovascular Research Institute Maastricht"},{"DOI":"10.13039\/100016244","name":"Health Foundation Limburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Empagliflozin is an effective treatment for heart failure with preserved ejection fraction (HFpEF), but its definite mechanism of action is unclear. Systemic microvascular dysfunction strongly relates to HFpEF aetiology, and we hypothesised that empagliflozin improves microvascular function in HFpEF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To investigate the effect of the sodium\u2013glucose cotransporter-2 inhibitor empagliflozin on peripheral microvascular function in HFpEF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a pre-post intervention study in patients diagnosed with HFpEF who are eligible for treatment with empagliflozin. Microvascular function assessment using laser speckle contrast analysis of the dorsal forearm during iontophoresis of vasoactive stimuli (acetylcholine, insulin sodium nitroprusside) was performed at baseline and after 3 months of empagliflozin treatment (10\u00a0mg daily). The primary outcome was the difference in blood flow measured in the forearm microvasculature between baseline and at follow-up (cutaneous vascular conductance, CVC). Secondarily we investigated quality-of-life based on the EQ-5D-5\u00a0L questionnaire at baseline and follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty six patients finished the study according to protocol (mean age of 74\u2009\u00b1\u20097 years, 62% female). We observed a decreased blood flow response to acetylcholine after 3 months of empagliflozin (CVC: 0.77\u2009\u00b1\u20090.24 vs. 0.64\u2009\u00b1\u20090.20, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In contrast, the response to insulin improved (CVC: 0.61\u2009\u00b1\u20090.43 vs. 0.81\u2009\u00b1\u20090.32, <jats:italic>p<\/jats:italic>\u2009=\u20090.03), and the response to sodium nitroprusside remained stable after 3 months. No significant correlations were found between the changes in blood flow and quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study shows that three months treatment with empagliflozin changed peripheral microvascular function in patients with HFpEF. Empagliflozin may enhance microvascular blood flow specifically via vascular actions of insulin, rather than a general effect on endothelial vasoregulation or smooth muscle cell function. As such, systemic microvascular dysfunction can be a modifiable factor in patients with HFpEF, while the clinical implications thereof warrant further investigations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The trial was preregistered at clinicaltrials.gov (NCT06046612).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02679-8","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T09:41:30Z","timestamp":1745574090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction"],"prefix":"10.1186","volume":"24","author":[{"given":"Sanne G. J.","family":"Mourmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Achten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijne J. E.","family":"Scheepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertje","family":"Swennen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Woudstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry van","family":"Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Schalkwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Knackstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerremy","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa P. M.","family":"van Empel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"2679_CR1","doi-asserted-by":"crossref","unstructured":"Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A, Khan JN, Chan DCS, Squire IB, Ng LL et al. Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction. JACC: Cardiovasc Imaging 2022.","DOI":"10.1016\/j.jcmg.2021.11.022"},{"issue":"4","key":"2679_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"2679_CR3","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780\u201392.","journal-title":"Eur Heart J"},{"issue":"3","key":"2679_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ejhf.1671","volume":"22","author":"JH Yang","year":"2020","unstructured":"Yang JH, Obokata M, Reddy YNV, Redfield MM, Lerman A, Borlaug BA. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):432\u201341.","journal-title":"Eur J Heart Fail"},{"issue":"37","key":"2679_CR5","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","volume":"39","author":"SJ Shah","year":"2018","unstructured":"Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Ljung Fax\u00e9n U, Fermer ML, Broberg MA, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439\u201350.","journal-title":"Eur Heart J"},{"issue":"18","key":"2679_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jacc.2012.07.036","volume":"60","author":"E Akiyama","year":"2012","unstructured":"Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2012;60(18):1778\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2679_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cardfail.2015.09.003","volume":"22","author":"S Mar\u00e9chaux","year":"2016","unstructured":"Mar\u00e9chaux S, Samson R, van Belle E, Breyne J, de Monte J, D\u00e9drie C, Chebai N, Menet A, Banfi C, Bouabdallaoui N, et al. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail. 2016;22(1):3\u201311.","journal-title":"J Card Fail"},{"key":"2679_CR8","doi-asserted-by":"crossref","unstructured":"Weerts J, Mourmans SGJ, Barandiar\u00e1n Aizpurua A, Schroen BLM, Knackstedt C, Eringa E, Houben A, van Empel VPM. The role of systemic microvascular dysfunction in heart failure with preserved ejection fraction. Biomolecules 2022, 12(2).","DOI":"10.3390\/biom12020278"},{"issue":"10","key":"2679_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","volume":"6","author":"CJ Rush","year":"2021","unstructured":"Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, Murphy CL, Ford TJ, Sidik N, McEntegart MB, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(10):1130\u201343.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2679_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/eurheartj\/ehx721","volume":"39","author":"VR Taqueti","year":"2018","unstructured":"Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018;39(10):840\u20139.","journal-title":"Eur Heart J"},{"issue":"9","key":"2679_CR11","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2337\/dc18-2515","volume":"42","author":"J Tromp","year":"2019","unstructured":"Tromp J, Lim SL, Tay WT, Teng T-HK, Chandramouli C, Ouwerkerk W, Wander GS, Sawhney JPS, Yap J, MacDonald MR, et al. Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care. 2019;42(9):1792\u20139.","journal-title":"Diabetes Care"},{"issue":"16","key":"2679_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"2679_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, Boer RAd, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Eng J Med. 2022;387(12):1089\u201398.","journal-title":"N Eng J Med"},{"issue":"4","key":"2679_CR14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00125-023-06068-2","volume":"67","author":"AG Hoek","year":"2024","unstructured":"Hoek AG, Dal Canto E, Wenker E, Bindraban N, Handoko ML, Elders PJM, Beulens JWJ. Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia. 2024;67(4):574\u2013601.","journal-title":"Diabetologia"},{"issue":"22","key":"2679_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"2679_CR16","first-page":"100725","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725\u2013100725.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"2679_CR17","doi-asserted-by":"publisher","first-page":"147916412097525","DOI":"10.1177\/1479164120975256","volume":"17","author":"G Langslet","year":"2020","unstructured":"Langslet G, Zinman B, Wanner C, Hantel S, Espadero RM, Fitchett D, Johansen OE. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(\u00ae). Diab Vasc Dis Res. 2020;17(6):1479164120975256.","journal-title":"Diab Vasc Dis Res"},{"key":"2679_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","volume":"167","author":"JRB Dyck","year":"2022","unstructured":"Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, Zuurbier CJ. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol. 2022;167:17\u201331.","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"2679_CR19","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690\u2013700.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2679_CR20","doi-asserted-by":"publisher","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, Lu Q, Qiu Y, do Carmo JM, Wang Z, da Silva AA, Mouton A, Omoto ACM, Hall ME, Li J, et al. Direct cardiac actions of the sodium glucose co-transporter 2 inhibitor empagliflozin improve myocardial oxidative phosphorylation and attenuate pressure\u2010overload heart failure. J Am Heart Assoc. 2021;10(6):e018298.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2679_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/CIRCULATIONAHA.122.062769","volume":"147","author":"KA Connelly","year":"2023","unstructured":"Connelly KA, Mazer CD, Puar P, Teoh H, Wang C-H, Mason T, Akhavein F, Chang C-W, Liu M-H, Yang N-I, et al. Empagliflozin and left ventricular remodeling in people without diabetes: primary results of the EMPA-HEART 2 cardiolink-7 randomized clinical trial. Circulation. 2023;147(4):284\u201395.","journal-title":"Circulation"},{"issue":"21","key":"2679_CR22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"key":"2679_CR23","doi-asserted-by":"publisher","first-page":"875327","DOI":"10.3389\/fcvm.2022.875327","volume":"9","author":"H Zhou","year":"2022","unstructured":"Zhou H, Peng W, Li F, Wang Y, Wang B, Ding Y, Lin Q, Zhao Y, Pan G, Wang X. Effect of sodium\u2013glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials. Front Cardiovasc Med. 2022;9:875327.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"2679_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M, Helmes M, Musters RJP, van der Velden J, Koolwijk P, Paulus WJ, van Hinsbergh VWM. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci. 2019;4(5):575\u201391.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2679_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, Pabel S, Tian Y, L\u00f3di M, Herwig M, Carrizzo A, Zhazykbayeva S, Kov\u00e1cs \u00c1, F\u00fcl\u00f6p G, Falc\u00e3o-Pires I, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117(2):495\u2013507.","journal-title":"Cardiovasc Res"},{"issue":"15","key":"2679_CR26","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue M, Li T, Wang Y, Chang Y, Cheng Y, Lu Y, Liu X, Xu L, Li X, Yu X, et al. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin Sci. 2019;133(15):1705\u201320.","journal-title":"Clin Sci"},{"issue":"1","key":"2679_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"HC Lee","year":"2019","unstructured":"Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019;18(1):45.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2679_CR28","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, et al. The SGLT2 inhibitor Dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954\u201360.","journal-title":"Nat Med"},{"issue":"7","key":"2679_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ejhf.1486","volume":"21","author":"WT Abraham","year":"2019","unstructured":"Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, et al. Rationale and design of the EMPERIAL-preserved and EMPERIAL-reduced trials of empagliflozin in patients with chronic heart failure. Eur J Heart Fail. 2019;21(7):932\u201342.","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"2679_CR30","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"3","key":"2679_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ejhf.1614","volume":"22","author":"A Barandiar\u00e1n Aizpurua","year":"2020","unstructured":"Barandiar\u00e1n Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca H-P, Henkens M, Heymans S, Beussink-Nelson L, Shah SJ, van Empel VPM. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413\u201321.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2679_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ecl.2008.06.001","volume":"37","author":"R Muniyappa","year":"2008","unstructured":"Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am. 2008;37(3):685\u2013711. ix-x.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"2679_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.mvr.2012.01.004","volume":"83","author":"I Cordovil","year":"2012","unstructured":"Cordovil I, Huguenin G, Rosa G, Bello A, K\u00f6hler O, de Moraes R, Tibiri\u00e7\u00e1 E. Evaluation of systemic microvascular endothelial function using laser speckle contrast imaging. Microvasc Res. 2012;83(3):376\u20139.","journal-title":"Microvasc Res"},{"issue":"1","key":"2679_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mvr.2010.11.002","volume":"81","author":"E Tesselaar","year":"2011","unstructured":"Tesselaar E, Sj\u00f6berg F. Transdermal iontophoresis as an in-vivo technique for studying microvascular physiology. Microvasc Res. 2011;81(1):88\u201396.","journal-title":"Microvasc Res"},{"issue":"2","key":"2679_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.mvr.2007.08.001","volume":"75","author":"RT de Jongh","year":"2008","unstructured":"de Jongh RT, Sern\u00e9 EH, Ijzerman RG, J\u00f8rstad HT, Stehouwer CDA. Impaired local microvascular vasodilatory effects of insulin and reduced skin microvascular vasomotion in obese women. Microvasc Res. 2008;75(2):256\u201362.","journal-title":"Microvasc Res"},{"issue":"5","key":"2679_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1210\/er.2007-0006","volume":"28","author":"R Muniyappa","year":"2007","unstructured":"Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28(5):463\u201391.","journal-title":"Endocr Rev"},{"key":"2679_CR37","doi-asserted-by":"publisher","first-page":"156146","DOI":"10.4061\/2011\/156146","volume":"2011","author":"MA Ozkor","year":"2011","unstructured":"Ozkor MA, Quyyumi AA. Endothelium-derived hyperpolarizing factor and vascular function. Cardiol Res Pract. 2011;2011:156146.","journal-title":"Cardiol Res Pract"},{"issue":"10","key":"2679_CR38","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"4","key":"2679_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MMV K MV","year":"2016","unstructured":"K MV MMV, de Wit SMAAE, Prenger GA, E AS. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343\u201352.","journal-title":"Value Health"},{"issue":"8","key":"2679_CR40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hec.1608","volume":"19","author":"NJ Devlin","year":"2010","unstructured":"Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ. 2010;19(8):886\u2013905.","journal-title":"Health Econ"},{"key":"2679_CR41","doi-asserted-by":"crossref","unstructured":"Abdulle AE, Bourgonje AR, Kieneker LM, Koning AM, la Bastide-van Gemert S, Bulthuis MLC, Dijkstra G, Faber KN, Dullaart RPF, Bakker SJL, et al. Serum free thiols predict cardiovascular events and all-cause mortality in the general population: a prospective cohort study. BMC Med. 2020;18(1):130.","DOI":"10.1186\/s12916-020-01587-w"},{"issue":"1","key":"2679_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12933-023-01935-z","volume":"22","author":"ED Canto","year":"2023","unstructured":"Canto ED, van Deursen L, Hoek AG, Elders PJM, den Ruijter HM, van der Velden J, van Empel V, Sern\u00e9 EH, Eringa EC, Beulens JWJ. Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: the Hoorn diabetes care system cohort. Cardiovasc Diabetol. 2023;22(1):234.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2679_CR43","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1152\/ajpendo.00267.2023","volume":"326","author":"LA Jahn","year":"2024","unstructured":"Jahn LA, Hartline LM, Nguyen T, Aylor K, Horton WB, Liu Z, Barrett EJ. Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes. Am J Physiol Endocrinol Metab. 2024;326(3):E258\u201367.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2679_CR44","doi-asserted-by":"crossref","unstructured":"Li C, Qin D, Hu J, Yang Y, Hu D, Yu B. Inflamed adipose tissue: A culprit underlying obesity and heart failure with preserved ejection fraction. Front Immunol 2022, 13.","DOI":"10.3389\/fimmu.2022.947147"},{"issue":"10","key":"2679_CR45","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","volume":"128","author":"WJ Paulus","year":"2021","unstructured":"Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis. Circ Res. 2021;128(10):1451\u201367.","journal-title":"Circ Res"},{"issue":"6","key":"2679_CR46","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/jdi.13289","volume":"11","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima KR, Takamura T, Taguchi I, Hisauchi I, Toyoda S, et al. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: the placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial. J Diabetes Investig. 2020;11(6):1551\u201363.","journal-title":"J Diabetes Investig"},{"key":"2679_CR47","doi-asserted-by":"publisher","first-page":"104008","DOI":"10.1016\/j.mvr.2020.104008","volume":"130","author":"M Jakubowski","year":"2020","unstructured":"Jakubowski M, Turek-Jakubowska A, Szahidewicz-Krupska E, Gawrys K, Gawrys J, Doroszko A. Profiling the endothelial function using both peripheral artery tonometry (EndoPAT) and laser doppler flowmetry (LD)\u2014complementary studies or waste of time? Microvasc Res. 2020;130:104008.","journal-title":"Microvasc Res"},{"issue":"4","key":"2679_CR48","first-page":"454","volume":"11","author":"AB Gevaert","year":"2023","unstructured":"Gevaert AB, B\u00f6hm B, Hartmann H, Goovaerts I, Stoop T, Heyning CMVD, Beckers PJ, Baldassarri F, Mueller S, Oberhoffer R, et al. Effect of training on vascular function and repair in heart failure with preserved ejection fraction. JACC: Heart Fail. 2023;11(4):454\u201364.","journal-title":"JACC: Heart Fail"},{"issue":"15","key":"2679_CR49","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.105.563213","volume":"113","author":"JA Kim","year":"2006","unstructured":"Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888\u2013904.","journal-title":"Circulation"},{"issue":"7","key":"2679_CR50","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EC-20-0082","volume":"9","author":"Y Goto","year":"2020","unstructured":"Goto Y, Otsuka Y, Ashida K, Nagayama A, Hasuzawa N, Iwata S, Hara K, Tsuruta M, Wada N, Motomura S, et al. Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use. Endocr Connect. 2020;9(7):599\u2013606.","journal-title":"Endocr Connect"},{"issue":"11","key":"2679_CR51","doi-asserted-by":"publisher","first-page":"107703","DOI":"10.1016\/j.jdiacomp.2020.107703","volume":"34","author":"S Sakurai","year":"2020","unstructured":"Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: association with improvement of fibrinolysis. J Diabetes Complications. 2020;34(11):107703.","journal-title":"J Diabetes Complications"},{"key":"2679_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.vph.2015.09.002","volume":"78","author":"MP de Boer","year":"2016","unstructured":"de Boer MP, Meijer RI, Richter EA, van Nieuw Amerongen GP, Sipkema P, van Poelgeest EM, Aman J, Kokhuis TJA, Koolwijk P, van Hinsbergh VWM, et al. Globular adiponectin controls insulin-mediated vasoreactivity in muscle through AMPK\u03b12. Vasc Pharmacol. 2016;78:24\u201335.","journal-title":"Vasc Pharmacol"},{"issue":"3\u20134","key":"2679_CR53","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000501100","volume":"143","author":"A Chowdhury Mohammed","year":"2019","unstructured":"Chowdhury Mohammed A, Moukarbel George V, Gupta R, Frank Stephanie M, Anderson Ann M, Liu Lijun C, Khouri Samer J. Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension. Cardiology. 2019;143(3\u20134):124\u201333.","journal-title":"Cardiology"},{"issue":"1","key":"2679_CR54","first-page":"8609213","volume":"2020","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxidative Med Cell Longev. 2020;2020(1):8609213.","journal-title":"Oxidative Med Cell Longev"},{"issue":"5","key":"2679_CR55","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1161\/01.ATV.0000122852.22604.78","volume":"24","author":"A Ceriello","year":"2004","unstructured":"Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24(5):816\u201323.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"2679_CR56","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/01.CIR.0000129772.26647.6F","volume":"109","author":"EH Jongh RTd, Sern\u00e9","year":"2004","unstructured":"Jongh RTd, Sern\u00e9 EH, IJzerman RG. Vries Gd, Stehouwer CDA: impaired microvascular function in obesity. Circulation. 2004;109(21):2529\u201335.","journal-title":"Circulation"},{"issue":"9","key":"2679_CR57","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jacbts.2023.05.007","volume":"8","author":"M Takano","year":"2023","unstructured":"Takano M, Kondo H, Harada T, Takahashi M, Ishii Y, Yamasaki H, Shan T, Akiyoshi K, Shuto T, Teshima Y, et al. Empagliflozin suppresses the differentiation\/maturation of human epicardial preadipocytes and improves paracrine secretome profile. JACC Basic Transl Sci. 2023;8(9):1081\u201397.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2679_CR58","doi-asserted-by":"publisher","first-page":"e000783","DOI":"10.1136\/bmjdrc-2019-000783","volume":"7","author":"L Xu","year":"2019","unstructured":"Xu L, Nagata N, Chen G, Nagashimada M, Zhuge F, Ni Y, Sakai Y, Kaneko S, Ota T. Empagliflozin reverses obesity and insulin resistance through fat Browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care. 2019;7(1):e000783.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"2679_CR59","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/nm788","volume":"8","author":"T Yamauchi","year":"2002","unstructured":"Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288\u201395.","journal-title":"Nat Med"},{"key":"2679_CR60","doi-asserted-by":"publisher","first-page":"112563","DOI":"10.1016\/j.biopha.2021.112563","volume":"146","author":"M Entezari","year":"2022","unstructured":"Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, Hashemi M, Hushmandi K, Ashrafizadeh M, Zarrabi A, et al. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomed Pharmacother. 2022;146:112563.","journal-title":"Biomed Pharmacother"},{"key":"2679_CR61","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai C, Guo Z, Chang X, Li Z, Wu F, He J, Cao T, Wang K, Shi N, Zhou H, et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 2022;52:102288.","journal-title":"Redox Biol"},{"key":"2679_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated Inhibition of mitochondrial fission. Redox Biol. 2018;15:335\u201346.","journal-title":"Redox Biol"},{"issue":"1","key":"2679_CR63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/cvr\/cvad162","volume":"120","author":"MB Nielsen","year":"2023","unstructured":"Nielsen MB, \u00c7olak Y, Benn M, Mason A, Burgess S, Nordestgaard BG. Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large-scale observational and Mendelian randomization evidence. Cardiovasc Res. 2023;120(1):95\u2013107.","journal-title":"Cardiovasc Res"},{"key":"2679_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jare.2024.02.015","volume":"68","author":"W Tan","year":"2025","unstructured":"Tan W, Wang Y, Cheng S, Liu Z, Xie M, Song L, Qiu Q, Wang X, Li Z, Liu T, et al. AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis. J Adv Res. 2025;68:299\u2013315.","journal-title":"J Adv Res"},{"issue":"5","key":"2679_CR65","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/00005344-199611000-00014","volume":"28","author":"H Shimokawa","year":"1996","unstructured":"Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol. 1996;28(5):703\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"2679_CR66","doi-asserted-by":"publisher","first-page":"H2462","DOI":"10.1152\/ajpheart.2001.280.6.H2462","volume":"280","author":"A Huang","year":"2001","unstructured":"Huang A, Sun D, Carroll MA, Jiang H, Smith CJ, Connetta JA, Falck JR, Shesely EG, Koller A, Kaley G. EDHF mediates flow-induced dilation in skeletal muscle arterioles of female eNOS-KO mice. Am J Physiol Heart Circ Physiol. 2001;280(6):H2462\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2679_CR67","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1006\/bbrc.2001.6278","volume":"290","author":"T Matoba","year":"2002","unstructured":"Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, Hirakawa Y, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002;290(3):909\u201313.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02679-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:01:32Z","timestamp":1745578892000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2679"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02679-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the declaration of Helsinki and was approved by the Medical Ethics Committee University Hospital Maastricht\/ Maastricht University as a low-intervention clinical trial according to the Clinical Trial Regulation (EU CT 2022-501682-45). All patients provided written informed consent before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.P.M.v.E received sponsoring\/grants from Roche, Vifor Pharma, Boehringer Ingelheim, Astra Zeneca and Pfizer (paid to institute), and received consultancy fees from Novartis, Janssen, Boehringer Ingelheim, Novonordisk (paid to institute).Pfizer and Astra Zeneca provided an unrestricted research grant to Maastricht University Medical Centre.C.K. received consulting fees from Pfizer, Novartis, BMS, and Alnylam (paid to institute).J.W. received grants from Corvia Medical, CSL Vifor, and Boehringer Ingelheim and is a member of the scientific committee on Atrial Disorders of the Heart Failure Association of the European society of cardiology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}